Mirum Pharmaceuticals (MIRM) Stock Analysis & Winston Score

Mirum Pharmaceuticals is a specialty drug company focused on rare liver diseases, particularly in children. Its main approved products are Livmarli (maralixibat), used to treat cholestatic liver diseases like Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), and Chenodal, used for a rare bile acid disorder. Its customers are hospitals, specialty clinics, and patients with these uncommon conditions, which affect a small but underserved population. Mirum makes money by selling its prescription drugs directly to patients and healthcare providers, often through specialty pharmacies. The company operates primarily in the United States but has been expanding into international markets. Its high gross margin of over 80% reflects the pricing power that comes with rare-disease drugs that have few or no alternatives — this is a key part of its competitive position. The main risk is that Mirum is still unprofitable, spending heavily on research and commercial expansion, so it depends on continued revenue growth from Livmarli to eventually reach sustainable earnings.